Exchange Traded Concepts LLC Sells 60,810 Shares of Pfizer Inc. $PFE

Key Points

• Exchange Traded Concepts reduced its Pfizer stake by 5.2%, selling 60,810 shares and finishing the quarter with 1,101,978 shares valued at about $27.44 million.
• Q4 results beat expectations—EPS $0.66 vs. $0.57 and revenue $17.56B vs. $16.93B—although revenue was down 1.2% year‑over‑year and analysts’ consensus rating is a Hold with a $28.19 target.
• Late‑stage clinical wins (including a partnered Lyme vaccine showing ~75% Phase‑3 efficacy) have spurred bullish notes, but political pricing risks and concerns about dividend sustainability create material downside risks to valuation.

Exchange Traded Concepts LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,101,978 shares of the biopharmaceutical company's stock after selling 60,810 shares during the quarter. Exchange Traded Concepts LLC's holdings in Pfizer were worth $27,439,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its stake in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after buying an additional 6,415 shares during the period. Employees Retirement System of Texas acquired a new position in Pfizer during the 2nd quarter worth approximately $1,711,000. Finally, GM Advisory Group LLC boosted its holdings in Pfizer by 1.5% in the second quarter. GM Advisory Group LLC now owns 30,884 shares of the biopharmaceutical company's stock worth $749,000 after acquiring an additional 450 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.03 on Friday. The company has a market cap of $153.70 billion, a PE ratio of 19.88 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The business has a 50 day moving average price of $26.84 and a 200-day moving average price of $25.68. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Pfizer's quarterly revenue was down 1.2% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PFE shares. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an "underperform" rating in a research note on Wednesday, December 17th. Bank of America cut their target price on Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Monday, December 15th. BMO Capital Markets reissued an "outperform" rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Zacks Research upgraded shares of Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. Finally, Royal Bank Of Canada initiated coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.19.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.